Andere talen Demant A/S

Aandelen

DEMANT

DK0060738599

Medische apparatuur, benodigdheden & distributie

Beurs gesloten - Nasdaq Copenhagen Andere beurzen 17:20:00 10-06-2026			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
253,80 ^DKK	-0,86%		+2,17%	+17,94%

06:13	Barclays verhoogt koersdoel voor Demant naar 240 Deense kroon (210), herhaalt gelijkgewogen advies - BN	FW
09/06	BofA verhoogt advies Demant naar kopen, positiever over markt voor gehoorapparaten	FW

Andere talen

06/05	Aktien Schweiz Schluss: Hoffnungen auf Frieden im Iran treiben Kurse
06/05	Aktien Schweiz mit Hoffnungen auf Iran-Kriegsende sehr fest
06/05	Demant: Q1 sales beat and strong confidence in 2026 outlook are noteworthy
06/05	Demant A/S: Expansion of Demant's Executive Leadership Team
06/05	Demant A/S: Expansion of Demant’s Executive Leadership Team
06/05	Demant A/S Announces President of the Hearing Aids Business Area Changes
06/05	Demant Q1 group organic growth of 6%
05/05	Demant A/S: Interim Management Statement for Q1 2026
22/04	DAX-Stagnation - Geopolitik bleibt bestimmendes Thema
08/04	Demant Lowers Share Capital
08/04	Demant A/S: Completion of capital reduction
07/04	Demant A/S: Transactions with Demant shares by managers and closely related parties
31/03	Demant Completes Oticon Medical Sale to Impilo
31/03	Demant A/S: Investor news - Demant completes divestment of Oticon Medical
31/03	U.S. Futures Rise, European Stocks Mostly Down
23/03	Sonova sets 'ambitious' medium-term targets, shares fall
16/03	La adquisición del negocio de audífonos de GN Store Nord por parte de Amplifon presionará su valoración -- Market Talk
05/03	Demant board elects Kristian Villumsen as chairperson
05/03	Demant A/S: Decisions of annual general meeting
05/03	Demant A/S Announces Board Changes
05/03	Europee in rosso, sul Mib Nexi crolla dopo i conti
05/03	Amplifon lascia mercato UK cedendo 100 cliniche a Hidden Hearing
20/02	Sonova expects FY revenue at lower end of target range, CEO says in interview
04/02	Cession chez AMS-Osram, OPA sur Beazley, coup de massue chez Novo Nordisk
04/02	Avis d'analystes du jour : ça s'agite sur Publicis, SSB, Eurofins et Amundi